Related Experiment Video
Updated: May 13, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
A randomized controlled trial comparing two ways of providing evidence-based drug information to GPs
Ingmarie Skoglund1, Cecilia Björkelund, Max Petzold
1Department of Public Health and Community Medicine/Primary Health Care, Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg, Sweden. ingmarie.skoglund@vgregion.se
Objective:
To investigate whether tailored evidence-based drug information (EBDI) to general practitioners (GPs) can change the proportion of ACE inhibitor prescriptions more effectively than EBDI provided as usual three and six months after the intervention.
Design:
Randomized controlled trial.
Setting:
GPs in southern Sweden working at primary health care centres (PHCCs) in seven drug and therapeutic committee areas.
Intervention:
EBDI tailored to motivational interviewing (MI) technique and focused on the benefit aspect was compared with EBDI provided as usual.
Subjects:
There were 408 GPs in the intervention group and 583 GPs in the control group.
Main Outcome Measures:
Change in proportion of ACE inhibitor prescriptions relative to the sum of ACE inhibitors and angiotensin receptor blockers, three and six months after the intervention.
Results:
The GPs' average proportions of prescribed ACE inhibitors increased in both groups. No statistically significant differences in the change of proportions were found between intervention and control groups. Information was provided to 29% of GPs in both groups.
Conclusion:
This study could not prove that specially tailored EBDI using MI implements guidelines more effectively than EBDI provided as usual.
Related Concept Videos
Blinding
Blind Procedures
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmacogenomics: Identification of New Drug Targets
